Canada approves Visible Genetic's HIV genotyping test:
This article was originally published in Clinica
Visible Genetics says it has become the first to gain a licence to market an HIV genotyping product in Canada. The Trugene genotyping test and hardware, components of the company's OpenGene system, can be sold for routine clinical or research use, says the Toronto, Ontario firm. Canada is the third country after Argentina and France that has approved the genotyping test. The product is currently under review by the US FDA (see Clinica No 965, p 21).
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.